Original Research Prim Care Companion CNS Disord June 2022

Effectiveness and Tolerability of Supratherapeutic Dosing of Vortioxetine in Patients With Treatment-Resistant Depression

PCC CNS Disord 2022;24(3):10.4088/PCC.21m03078

Full Article Read the complete peer-reviewed article in Prim Care Companion CNS Disord. PCC CNS Disord 2022;24(3):10.4088/PCC.21m03078 Clinical Summary Patients with treatment-resistant depression often remain symptomatic after multiple antidepressant trials, and standard next-step options are not always available or feasible. This article addresses a practical question for such patients: whether increasing vortioxetine above the approved 20 mg/d maximum can improve depressive severity without introducing serious tolerability problems. FAQ What did this study find about vortioxetine doses above 20 mg/day in treatment-resistant depression? 8 questions
Key Takeaways The cohort was clinically difficult to treat: treatment-resistant depression required failure of 2 or more different oral antidepressants, baseline severity was high with a Montgomery-Asberg Depression Rating Scale score ≥ 20, and 38 patients were receiving concomitant medications when vortioxetine was escalated. 5 takeaways Clinical Guide How should clinicians use and monitor supratherapeutic vortioxetine in adults with treatment-resistant depression? 7 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe